Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis

NCT00532532 is registered in ClinicalTrials.gov with Avigen as lead sponsor.

NCT NCT00532532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00532532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AV650-018: A Two-Part (Double-Blind Followed by Open-Label), Placebo Controlled, Randomized Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of AV650 (Tolperisone HCl) in Subjects With Spasticity Associated With Multiple Sclerosis
Lead sponsor
Avigen
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2007
Completion date
November 30, 2008
Enrollment
150 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

muscle spasticity